Scholarlink

Background <p>MMA and CBS deficiency are rare autosomal recessive metabolic disorders caused by defects in cobalamin metabolism and cystathionine-beta-synthase activity, respectively. Advanced molecular genetic techniques, have become essential for diagnosing these conditions. This study aimed to analyze the genetic variations in three MMA and four CBS deficiency cases using WES and correlate the findings with clinical, biochemical, and treatment outcomes.</p> Methods <p>Clinical evaluation, biochemical testing, neuroimaging, and WES were performed. WES data were analyzed using the reference genome GRCh37, and variants were classified according to ACMG guidelines. Treatment outcomes were monitored for three months post-intervention.</p> Results <p>In MMA cases, a homozygous pathogenic variant (c.394 C &gt; T, p.Arg132Ter) in <i>MMACHC</i> was identified in all three patients. Biochemical abnormalities included methylmalonic aciduria, elevated homocysteine, and megaloblastic anemia. Hydroxycobalamin therapy improved behavioral, cognitive, and dermatological symptoms, though residual neuropathy persisted in one case. In CBS deficiency, pathogenic variants in <i>CBS</i> (c.992 C &gt; T, p.Ala331Val; c.862 G &gt; A, p.Ala288Thr; c.700 G &gt; A, p.Asp234Asn) were identified. Clinical features included developmental delayed milestones, lens dislocation, and vascular complications. Treatment outcomes varied based on early diagnosis and compliance.</p> Conclusion <p>This study highlights the importance of newborn screening program with WES in diagnosing and managing MMA and CBS deficiency, facilitating early intervention, improving clinical outcomes, and supporting precision medicine approaches.</p> <p></p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Early newborn screening and diagnosis are critical for effective treatment and improved patient outcomes.</p> </ItemContent> <ItemContent> <p>Novel clinical and pathogenic variants will expand the current understanding of these disorders.</p> </ItemContent> <ItemContent> <p>WES enhances the diagnostic precision for MMA and CBS deficiency, facilitating timely intervention and superior clinical management.</p> </ItemContent> <ItemContent> <p>Accurate and early detection of treatable IEMs through NBS can significantly reduce disease burden and healthcare costs.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling clinical and genetic landscapes of MMA and CBS: insights from whole exome sequencing in a tertiary care setting

  • 期刊论文

  • 发表日期：

    2026年3月3日

查看全文
  • Muhammad Wasim,
  • Iram Javed,
  • Afia Iqbal,
  • Nadia Mustafa,
  • Haq Nawaz Khan,
  • Tipu Sultan,
  • Yajun Wang,
  • Guoda Ma

摘要

Background

MMA and CBS deficiency are rare autosomal recessive metabolic disorders caused by defects in cobalamin metabolism and cystathionine-beta-synthase activity, respectively. Advanced molecular genetic techniques, have become essential for diagnosing these conditions. This study aimed to analyze the genetic variations in three MMA and four CBS deficiency cases using WES and correlate the findings with clinical, biochemical, and treatment outcomes.

Methods

Clinical evaluation, biochemical testing, neuroimaging, and WES were performed. WES data were analyzed using the reference genome GRCh37, and variants were classified according to ACMG guidelines. Treatment outcomes were monitored for three months post-intervention.

Results

In MMA cases, a homozygous pathogenic variant (c.394 C > T, p.Arg132Ter) in MMACHC was identified in all three patients. Biochemical abnormalities included methylmalonic aciduria, elevated homocysteine, and megaloblastic anemia. Hydroxycobalamin therapy improved behavioral, cognitive, and dermatological symptoms, though residual neuropathy persisted in one case. In CBS deficiency, pathogenic variants in CBS (c.992 C > T, p.Ala331Val; c.862 G > A, p.Ala288Thr; c.700 G > A, p.Asp234Asn) were identified. Clinical features included developmental delayed milestones, lens dislocation, and vascular complications. Treatment outcomes varied based on early diagnosis and compliance.

Conclusion

This study highlights the importance of newborn screening program with WES in diagnosing and managing MMA and CBS deficiency, facilitating early intervention, improving clinical outcomes, and supporting precision medicine approaches.

Impact

Early newborn screening and diagnosis are critical for effective treatment and improved patient outcomes.

Novel clinical and pathogenic variants will expand the current understanding of these disorders.

WES enhances the diagnostic precision for MMA and CBS deficiency, facilitating timely intervention and superior clinical management.

Accurate and early detection of treatable IEMs through NBS can significantly reduce disease burden and healthcare costs.